This paper is only available as a PDF. To read, Please Download here.
Objectives
In 2017, we estimated that more than one-third of women support advance provision
(44%) and over-the counter (OTC, 37%) access to medication abortion. We assess any
changes in national interest and support for these models of abortion care.
Methods
From December 2021 to January 2022, we administered a national probability-based online
survey of English- and Spanish-speaking people assigned female at birth regarding
their interest and support for accessing medication abortion in advance from a doctor
for future use and OTC without a prescription, using Ipsos KnowledgePanel. We estimated
weighted frequencies and conducted bivariate analyses to identify participant characteristics
associated with interest and support for each model.
Results
7,016 people assigned female at birth completed the survey. Nearly half stated they
were in favor of advance provision (49%) and OTC (49%) access to medication abortion.
The most common advantages of each model included privacy (51% and 44%), convenience
(48% and 50%) and earlier access to care (45% and 44%); the most common disadvantages
included taking the pills incorrectly (57% and 53%), unanswered questions (45% and
46%) and being forced to take the medications (43% and 41%). Experiencing barriers
accessing reproductive healthcare, mistreatment by healthcare providers and identifying
as a sexual and gender minority were associated with greater support for these models
of care.
Conclusions
There is growing national support for streamlined access to medication abortion, particularly
among those who have experienced challenges accessing healthcare. As legal restrictions
proliferate, these models of care have the potential to increase access to abortion.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
